AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie raised its 2025 earnings forecast after a strong Q2, despite $3 billion in deal costs tied to acquisitions of Capstan ...

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago. These figures are ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in its latest quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill., drugmaker said it logged earnings of $938 ...

AbbVie (ABBV) stock gains as the company raises outlook and reports better than expected Q2 2025 results, driven by its ...

AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong ...

AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which ...